The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Denosumab treatment for fibrous dysplasia
Open accessAbstract
Fibrous dysplasia (FD) is a skeletal disease caused by somatic activating mutations of the cyclic adenosine monophosphate (cAMP)-regulating protein, α-subunit of the Gs stimulatory protein (Gsα). These mutations lead to replacement of normal bone by proliferative osteogenic precursors, resulting in deformity, fracture, and pain. Medical treatment has been ineffective in altering the disease course. Receptor activator of NF-κB ligand (RANKL) is a cell-surface protein involved in many cellular processes, including osteoclastogenesis, and is reported to be overexpressed in FD-like bone cells. Denosumab is a humanized monoclonal antibody to RANKL approved for treatment of osteoporosis and prevention of skeletal-related events from bone metastases. We present the case of a 9-year-old boy with severe FD who was treated with denosumab for a rapidly expanding femoral lesion. Immunohistochemical staining on a pretreatment bone biopsy specimen revealed marked RANKL expression. He was started on monthly denosumab, with an initial starting dose of 1 mg/kg and planned 0.25 mg/kg dose escalations every 3 months. Over 7 months of treatment he showed marked reduction in pain, bone turnover markers (BTMs), and tumor growth rate. Denosumab did not appear to impair healing of a femoral fracture that occurred while on treatment. With initiation of treatment he developed hypophosphatemia and secondary hyperparathyroidism, necessitating supplementation with phosphorus, calcium, and calcitriol. BTMs showed rapid and sustained suppression. With discontinuation there was rapid and dramatic rebound of BTMs with cross-linked C-telopeptide (reflecting osteoclast activity) exceeding pretreatment levels, accompanied by severe hypercalcemia. In this child, denosumab lead to dramatic reduction of FD expansion and FD-related bone pain. Denosumab was associated with clinically significant disturbances of mineral metabolism both while on treatment and after discontinuation. Denosumab treatment of FD warrants further study to confirm efficacy and determine potential morbidity, as well as to determine the mechanism of RANKL in the pathogenesis of FD and related bone marrow stromal cell diseases. © 2012 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Activating Mutations of the Stimulatory G Protein in the McCune–Albright Syndrome
Weinstein, L. S., Shenker, A., Gejman, P. V., Merino, M. J., Friedman, E., & Spiegel, A. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112123252403 · Cited by 1,691
Stopeck, A. T., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,597
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
(2018) · Wiley eBooks · doi:10.1002/9781119266594 · Cited by 1,105
Albright, F., Butler, A. M., Hampton, A. O., et al. (1937) · New England Journal of Medicine · doi:10.1056/nejm193704292161701 · Cited by 1,057
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
Thomas, D., Henshaw, R., Skubitz, K., Chawla, S., Staddon, A., Blay, J.-Y., Roudier, M., Smith, J., Ye, Z., Sohn, W., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70010-3 · Cited by 716
FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting
Riminucci, M., Collins, M. T., Fedarko, N. S., Cherman, N., Corsi, A., White, K. E., Waguespack, S., Gupta, A., Hannon, T., Econs, M. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18399 · Cited by 657
Self-citationBone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y.-C., Grazette, L., San Martin, J., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 623
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
Gonzalez-Suarez, E., Jacob, A. P., Jones, J., Miller, R., Roudier-Meyer, M. P., Erwert, R., Pinkas, J., Branstetter, D., & Dougall, W. C. (2010) · Nature · doi:10.1038/nature09495 · Cited by 596
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J. A., Lee, H. J., Hanada, R., Joshi, P. A., Aliprantis, A., Glimcher, L., et al. (2010) · Nature · doi:10.1038/nature09387 · Cited by 592
Schwindinger, W. F., Francomano, C. A., & Levine, M. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.5152 · Cited by 502
Dumitrescu, C. E., & Collins, M. T. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-12 · Cited by 454
Self-citationAtypical fractures of the femur and bisphosphonate therapy
Giusti, A., Hamdy, N. A. T., & Papapoulos, S. E. (2010) · Bone · doi:10.1016/j.bone.2010.05.019 · Cited by 295
Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
Reid, I. R., Miller, P. D., Brown, J. P., Kendler, D. L., Fahrleitner-Pammer, A., Valter, I., Maasalu, K., Bolognese, M. A., Woodson, G., Bone, H., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.149 · Cited by 251
Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation.
Riminucci, M., Fisher, L. W., Shenker, A., Spiegel, A. M., Bianco, P., & Robey, P. G. (1997) · Europe PMC (PubMed Central) · Cited by 225
Bianco, P., Kuznetsov, S. A., Riminucci, M., Fisher, L. W., Spiegel, A. M., & Robey, P. G. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2361 · Cited by 225
Gerstenfeld, L. C., Sacks, D. J., Pelis, M., Mason, Z. D., Graves, D. T., Barrero, M., Ominsky, M. S., Kostenuik, P. J., Morgan, E. F., & Einhorn, T. A. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081113 · Cited by 218
Collins, M. T., Chebli, C., Jones, J., Kushner, H., Consugar, M., Rinaldo, P., Wientroub, S., Bianco, P., & Robey, P. G. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.5.806 · Cited by 189
Self-citationPrimer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
Favus, M. J., & Slovik, D. M. (1994) · The Endocrinologist · doi:10.1097/00019616-199403000-00013 · Cited by 149
RANK ligand as a therapeutic target for bone metastases and multiple myeloma
Roodman, G. D., & Dougall, W. C. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.002 · Cited by 142
Fibrous Dysplasia as a Stem Cell Disease
Riminucci, M., Saggio, I., Robey, P. G., & Bianco, P. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.06s224 · Cited by 127
Fizazi, K. S., Bosserman, L. D., Gao, G., Skácel, T., & Markus, R. A. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.11.022 · Cited by 110
Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas
Mikami, S., Katsube, K., Oya, M., Ishida, M., Kosaka, T., Mizuno, R., Mochizuki, S., Ikeda, T., Mukai, M., & Okada, Y. (2009) · The Journal of Pathology · doi:10.1002/path.2567 · Cited by 106
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice
Molyneux, S. D., Grappa, M. A. D., Beristain, A. G., McKee, T. D., Wai, D., Paderova, J., Kashyap, M., Hu, P., Maiuri, T., Narala, S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42391 · Cited by 101
Epi- and metaphyseal changes in children caused by administration of bisphosphonates.
van Meerten, E. L. V. P., Kroon, H. M., & Papapoulos, S. E. (1992) · Radiology · doi:10.1148/radiology.184.1.1609087 · Cited by 98
Piersanti, S., Remoli, C., Saggio, I., Funari, A., Michienzi, S., Sacchetti, B., Robey, P. G., Riminucci, M., & Bianco, P. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091036 · Cited by 96
Fizazi, K. S., Bosserman, L. D., Gao, G., Skácel, T., & Markus, R. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.04.023 · Cited by 95
Skeletal progenitors and the GNAS gene: fibrous dysplasia of bone read through stem cells
Riminucci, M., Robey, P. G., Saggio, I., & Bianco, P. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0097 · Cited by 83
Parisi, M. S., Oliveri, B., & Mautalén, C. (2003) · Bone · doi:10.1016/s8756-3282(03)00221-7 · Cited by 56
Sasaki, A., Ishikawa, K., Haraguchi, N., Inoue, H., Ishio, T., Shibata, K., Ohta, M., Kitano, S., & Mori, M. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9277-4 · Cited by 32
Cited by
Osteoclasts: more than ‘bone eaters’
Charles, J. F., & Aliprantis, A. O. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.001 · Cited by 391
Javaid, M. K., Boyce, A., Appelman-Dijkstra, N., Ong, J., Defabianis, P., Offiah, A., Arundel, P., Shaw, N., Pos, V. D., Underhil, A., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1102-9 · Cited by 321
Self-citationClinical guidelines for the management of craniofacial fibrous dysplasia
Lee, J., FitzGibbon, E., Chen, Y., Kim, H., Lustig, L., Akintoye, S., Collins, M., & Kaban, L. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-s1-s2 · Cited by 314
Self-citation
Metadata
- Authors
- Boyce, A. M., Chong, W. H., Yao, J., Gafni, R. I., Kelly, M. H., Chamberlain, C. E., Bassim, C., Cherman, N., Ellsworth, M., Kasa-Vubu, J. Z., Farley, F. A., Molinolo, A. A., Bhattacharyya, N., & Collins, M. T.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-19
- Volume
- 27
- Issue
- 7
- Pages
- 1462-1470
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2099963180
- Cited by
- 260
- References
- 32
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.